(2S,4s)-4-羟基-2-甲基-吡咯烷-1-羧酸叔丁酯 | 477293-60-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (2S,4s)-4-羟基-2-甲基-吡咯烷-1-羧酸叔丁酯
• 英文名称: tert-butyl (2S,4S)-4-hydroxy-2-methylpyrrolidine-1-carboxylate
• CAS: 477293-60-0
• 化学式: C₁₀H₁₉NO₃
• 分子量: 201.266
• InChiKey: BXZADLGAYWRZCR-YUMQZZPRSA-N

物化性质

• 沸点：
  282.5±33.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P280
• 危险性描述：
  H302,H317
• 储存条件：
  室温下保存，需密封并保持干燥。

反应信息

• 作为反应物：
  描述：

  (2S,4s)-4-羟基-2-甲基-吡咯烷-1-羧酸叔丁酯 在 sodium methylate 、 potassium carbonate 、 三苯基膦 、 三氟乙酸 、 potassium iodide 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 prop-2-enyl (1S,2S,4R,5R,8R,9S,11R)-2-[[(3R,5S)-1-benzyl-5-methylpyrrolidin-3-yl]sulfanylmethyl]-9-formyl-5-methyl-13-propan-2-yltetracyclo[7.4.0.02,11.04,8]tridec-12-ene-1-carboxylate
  参考文献：
  名称：

  Synthesis and evaluation of novel pyrrolidinyl sordaricin derivatives as antifungal agents

  摘要：

  N-Benzyl pyrrolidinyl sordaricin derivatives have been synthesized from cis-4-hydroxy-D-proline in a stereocontrolled manner. These compounds maintained moderate antifungal activity against several pathogenic fungal strains. Their MIC values against Candida albicans were in the range of 0.25-2 mug/mL. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00534-6
• 作为产物：
  描述：

  (2R,4S)-methyl 4-hydroxypyrrolidine-2-carboxylate 在 咪唑 、 锂硼氢 、 四丁基氟化铵 、 三乙基硼氢化锂 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 (2S,4s)-4-羟基-2-甲基-吡咯烷-1-羧酸叔丁酯
  参考文献：
  名称：

  Discovery of Novel Cyanamide-Based Inhibitors of Cathepsin C

  摘要：

  The discovery of potent and selective cyanamide-based inhibitors of the cysteine protease cathepsin C is detailed. Optimization of the template with regard to plasma stability led to the identification of compound 17, a potent cathepsin C inhibitor with excellent selectivity over other cathepsins and potent in vivo activity in a cigarette smoke mouse model.

  DOI：

  10.1021/ml100212k

文献信息

• TRANS-3,5-DISUBSTITUTEDPYRROLIDINE: ORGANOCATALYST FOR anti-MANNICH REACTIONS
  申请人：Tanaka Fujie

  公开号：US20070117986A1

  公开（公告）日：2007-05-24

  A compound of Formula I is disclosed, in which R is a substituent containing a hydrogen bond-forming atom within three atoms from the ring carbon to which the substituent is bonded; X is CH 2 , O, S or NR 1 , wherein R 1 is a hydrocarbyl group or an amino-protecting group having one to about 18 carbon atoms; R 2 is hydrido or a hydrocarbyl group containing one to about twelve carbon atoms; and R 3 is hydrido or methyl, but both R 2 and R 3 are not hydrido when X is CH 2 A molecule of Formula I and those in which R 2 and R 3 can both be hydrido (Formula X) functions as a catalyst in a Mannich reaction to asymmetrically form β-aminoaldehyde or β-aminoketone diastereomeric products having two chiral centers on adjacent carbon atoms and in which the anti-diastereomers are in excess over the syn-diastereomers. Methods for carrying out those syntheses are also disclosed.

  披露了一种公式I的化合物，其中R是含有一个在距离与亚基连接的环碳三个原子以内的氢键形成原子的取代基；X是CH2，O，S或NR1，其中R1是一个含有一个到约18个碳原子的烃基团或一个氨基保护基团；R2是氢化物或含有一个到约十二个碳原子的烃基团；R3是氢化物或甲基，但是当X是 时，R2和R3不能都是氢化物。公式I的分子以及其中R2和R3都可以是氢化物（公式X）的分子，在曼尼希反应中作为催化剂，非对称地形成具有相邻碳原子上的两个手性中心的β-氨基醛或β-氨基酮对映异构体产品，并且反式对映异构体过剩于顺式对映异构体。还披露了进行那些合成的方法。
• PYRAZOL DERIVATIVES
  申请人：Aebi Johannes

  公开号：US20090029963A1

  公开（公告）日：2009-01-29

  The invention is concerned with novel pyrazol derivatives of formula (I), wherein R 1 , R 2 , R 3 , R 4 , X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.

  这项发明涉及式(I)的新型吡唑衍生物， 其中 R 1 ，R 2 ，R 3 ，R 4 ，X和Y如本文所定义，以及其生理上可接受的盐。这些化合物是CCR-2受体和/或CCR-5受体的拮抗剂，可用作药物。
• [EN] NOVEL CATHEPSIN C INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE LA CATHEPSINE C ET LEUR UTILISATION
  申请人：GLAXO GROUP LTD

  公开号：WO2009026197A1

  公开（公告）日：2009-02-26

  The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD.

  这项发明涉及到符合以下式（I）的化合物，其中R1、R2a、R2b、R2c、R3和n的定义如下，并且其药用盐。它们是半胱氨酸蛋白酶C抑制剂，可用于治疗由半胱氨酸蛋白酶C酶介导的疾病，如慢性阻塞性肺病。
• PYRIMIDINE COMPOUND OR SALT THEREOF
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20210024530A1

  公开（公告）日：2021-01-28

  Provided are a novel pyrimidine compound that inhibits HER2 activity and exhibits brain penetration properties, or a salt thereof, and a pharmaceutical composition comprising the same. A compound represented by the following formula (I), or a salt thereof: wherein R 1 represents a C1-C4 alkyl group optionally having a C1-C4 alkoxy group as a substituent, or a C3-C4 cycloalkyl group; R 2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group optionally having 1 to 5 C1-C4 alkoxy groups or fluorine atoms each as a substituent(s), or a C1-C6 alkoxy group; R 3 represents a hydrogen atom, or a C1-C4 alkyl group optionally having 1 to 5 fluorine atoms as a substituent(s); R 4 represents a hydrogen atom or a C1-C4 alkyl group; and R 5 represents a phenyl group optionally having 1 to 3 substituents selected from fluorine atoms and chlorine atoms.

  提供了一种新型嘧啶化合物，抑制HER2活性并具有脑透过性，或其盐，以及包含该化合物的药物组合物。 表示为以下式（I）的化合物，或其盐： 其中R1代表一个C1-C4烷基基团，可选地具有一个C1-C4烷氧基作为取代基，或一个C3-C4环烷基团； R2代表氢原子，卤原子，一个C1-C6烷基基团，可选地具有1至5个C1-C4烷氧基或氟原子作为取代基，或一个C1-C6烷氧基； R3代表氢原子，或一个C1-C4烷基基团，可选地具有1至5个氟原子作为取代基； R4代表氢原子或一个C1-C4烷基基团；和 R5代表一个苯基，可选地具有1至3个取代基，选自氟原子和氯原子。
• [EN] PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA CONTENANT DE LA PYRROLIDINE ET DE LA BICYCLOHÉTÉROARYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021094312A1

  公开（公告）日：2021-05-20

  The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GIcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病，如tau病变，特别是阿尔茨海默病或进行性上行性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病，由帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍），具有Lewy小体的痴呆，多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。